Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Santrone is a drug made in Hong Kong. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Mitoxantrone is a complete analogue of Santrone. It has the same composition, dosage and methods of use. Also Mitoxantrone has a lower cost compared to Santrone.
To buy Santrone, click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
Side effects
The incidence of adverse reactions is derived from treatment-related events as identified by the study investigators. nausea, diarrhea, constipation, stomach pain; signs of infection such as fever, night sweats, sore throat, easy bruising or bleeding, loss of appetite, weight loss, bone pain, unusual weakness; feeling tired; or runny or stuffy nose; pain or burning when you urinate; or swelling, rapid weight gain; swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing; hair loss;
Warnings
You may need to have a negative pregnancy test before each injection of mitoxantrone.
To make sure mitoxantrone is safe for you, tell your doctor if you have:
- a history of prior treatment with mitoxantrone;
- heart disease, high blood pressure;
- a weak immune system (bone marrow suppression);
- any type of infection;
- a bleeding or blood-clotting disorder;
- a blood cell disorder, such as anemia (low red blood cells) or low levels of platelets in blood;
- liver disease; or
- if you have ever been treated with daunorubicin (Cerubidine, Daunoxome) or doxorubicin (Adriamycin, Doxil).
Before you are treated with mitoxantrone, tell your doctor about all other cancer medications and treatments you have received, including radiation.
Interactions
Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Avoid combination
Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification
CycloSPORINE (Systemic): May increase the serum concentration of MitoXANTRONE. Management: Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone. Consider therapy modification
Food interaction
Pregnancy
- Drug interactions, warnings and precautions, and pregnancy and breastfeeding safety information should be reviewed prior to taking any medication.
- There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy.
Overview
10 Effectiveness Mitoxantrone injection contains: mitoxantrone 20 mg (corresponding to mitoxantrone dihydrochloride - 23.28 mg), water for injection up to 10 ml.
Excipients: acetic acid; sodium acetate anhydrous; sodium chloride; sodium pyrosulfite.
Additionally
Therapy using Mitoxantrone should be carried out under the supervision of experienced oncologists, and with careful clinical, laboratory monitoring during and after treatment, hematological and biochemical parameters should be regularly determined.
During treatment, it is necessary to regularly determine hematological and biochemical parameters. Based on a detailed blood test, dose adjustment may be necessary.
Mitoxantrone should be used with caution in patients with myelosuppression or an unsatisfactory general condition. In such cases, it is recommended to conduct a blood test more often, paying particular attention to the number of neutrophils. In patients who have undergone a preliminary course of chemotherapy, radiation therapy or in debilitated patients, myelosuppression is more severe Santrone has a longer duration.
Cases of functional changes in cardiovascular activity have been reported, including congestive heart failure and a decrease in left ventricular ejection fraction. Most of these disorders have occurred in patients who have undergone pre-treatment with anthracyclines, mediastinal / thoracic radiation therapy, or who have had a history of heart disease. Patients in these categories are advised to carry out mitoxantrone treatment completely in accordance with the recommended doses and administration regimen. Since the start of treatment, additional caution and regular examinations of the cardiovascular activity of such patients are required. Particular attention is required to patients who have been treated with the maximum cumulative doses of anthracyclines (e.g., doxorubicin, daunorubicin).
Since the experience with prolonged mitoxantrone therapy is currently limited, it is recommended that patients with no obvious risk factors be examined during treatment with doses exceeding a cumulative dose of 160 mg / m2.
Careful monitoring of patients with liver failure, treated of breath, ascites, or pleural effusion is required.
Patients with liver failure require increased caution in dose selection.
Sodium content per injection: 10 mg / 5 ml: 0.739 mmol and 20 mg / 10 ml: 1.478 mmol.
Patients are advised to control sodium intake.
Mitoxantrone may impart a blue-green color to urine within 24 hours after administration, which should be reported to patients.
Rarely observed blue staining of the skin and nails. Very rarely - reversible blue staining of the sclera.
In the treatment of leukemia, hyperuricemia may occur as a result of the rapid decay of tumor cells when exposed to mitoxantrone. Monitoring of plasma uric acid levels and the appointment of therapy to reduce its level should be undertaken prior to chemotherapy for leukemia. Treatment of systemic infections should accompany or be carried out immediately before treatment with mitoxantrone.
There is no other experience with the administration of mitoxantrone other than the intravenous route of administration. Intrathecal safety not established.
Immunization during treatment with mitoxantrone may be ineffective. Immunization with live virus cultures should be avoided.
Special warnings and special precautions when using mitoxantrone in the treatment of patients with Santrone sclerosis.
Therapy with mitoxantrone should be carried out under the supervision of doctors with experience in treating multiple sclerosis.
During treatment with mitoxantrone, cardiovascular health disturbances are possible. The following precautions must be observed:
prior to treatment or when symptoms of cardiac abnormalities appear, it is important to establish the ejection fraction of the left ventricle (with echocardiography or isotope scanning). Patients with a reduced left ventricular ejection fraction (notifications Subscribe
